Reference and Resources

Table of Contents

Introduction

This section is designed to provide the Prescriber and the Patient with reference and resource information to better help you understand the research behind a particular formulation in a specific speciality, or a list of books that will provide an insight into a particular lifestyle therapy or disease state. There are two sections-- Prescriber Specialities, which provides a list of article abstracts titles by specific prescriber speciality, and Lifestyle Therapies, which provides a list of books and article abstracts for a specific lifestyle therapy or disease state. These lists will continue to grow over time as we learn more about each speciality and lifestyle therapy.

Prescriber Specialities

Bio-Identical Hormone Replacement (OB/Gyn) - For Women

  1. Gilson, M.D., Ph.D., George R., and David T. Zava, Ph.D. "A Perspective on HRT for Women: Picking Up the Pieces After The Women's Health Initiative Trial - Part 1." International Journal of Pharmaceutical Compounding Vol. 7, No. 4, (2003): 250 - 256.
  2. Gilson, M.D., Ph.D., George R., and David T. Zava, Ph.D. "A Perspective On HRT For Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2." International Journal of Pharmaceutical Compounding Vol. 7, No. 5, (2003): 330 - 338.
  3. Reed-Kane, Pharm.D., FIACP, FPCA, Dana,."Natural Hormone Replacement Therapy: What it is and What Consumers Really Want." International Journal of Pharmaceutical Compounding Vol. 5, No. 5, (2001): 332 - 335.

Bio-Identical Hormone Replacement (Andropause) - For Men

  1. Biundo, BSPharm., RPh, Bruce, and Eugene Shippen, M.D. "Testosterone Deficiency in Men: New Treatments for Andropause." International Journal of Pharmaceutical Compounding Vol. 4, No. 6, (2000): 429 - 430.
  2. Biundo, BSPharm., RPh, Bruce, "Treating Andropause: Prohormones and Hormone Metabolic Modifiers." International Journal of Pharmaceutical Compounding Vol. 5, No. 5, (2001): 351 - 353.
  3. Biundo, BSPharm., RPh, Bruce, "Andropause: New Perspectives." International Journal of Pharmaceutical Compounding Vol. 8, No. 3, (2004): 175 - 178.
  4. Cutter, M.D., Christopher B. "Compounded Testosterone Gels: A Guide for Clinicians and Pharmacist." International Journal of Pharmaceutical Compounding Vol. 4, No. 6, (2000): 432 - 437.
  5. Jonathan, Pharm.D. (Candidate), Bamrom H. "Andropause: A Review of Treatment Options." International Journal of Pharmaceutical Compounding Vol. 6, No. 6, (2002): 458 - 461.
  6. Kellis, J.T. "Inhibition of human estrogen synthetase (aromatase) by flavone." Science 225(4666)TVT (Sep 7, 1984): 1032-4.
  7. Meletis, N.D., Chris D. "Complementary Medical Approaches to Benign Postatic Hyperplasia." International Journal of Pharmaceutical Compounding Vol. 3, No. 2, (1999): 85 - 86. Addressing the hormonal and biochemical imbalances assoicated iwth natural aging results.
  8. Miller, N.D., Martin "Men's Health: Practical Solutions to a Profoundly Underrated Health-Care Crisis." International Journal of Pharmaceutical Compounding Vol. 3, No. 2, (1999): 76 - 79. Naturally oriented physicians and compounding pharmacists need to collaborate on constructive alternative therapies.
  9. Preckshot, R.Ph, FIACP, John "Male Impotency and the Compounding Pharmacist." International Journal of Pharmaceutical Compounding Vol. 3, No. 2, (1999): 80 - 83. The compounding Pharmacist can individualize combination therapeutic approaches.
  10. Tan, M.D., MBA, AGSF, Robert S. "Measuring Testosterone Biomarkers in Serum and Saliva: Are They Accurate?" u>International Journal of Pharmaceutical Compounding Vol. 8, No. 6, (2004): 419 - 423.
  11. Weise, Sr.,R.Ph., FACA, Gill "Use of Saw Palmetto and Pygeum in Men" International Journal of Pharmaceutical Compounding Vol. 3, No. 2, (1999): 99 - 100. Two plant porducts provide a natural treatmnet option for men with prostate problems.
  12. Wright, M.D., Jonathan, and Lane Lenard, Ph.D. "Natural Testosterone: Hormone of the Heart" International Journal of Pharmaceutical Compounding Vol. 3, No. 2, (1999): 88 - 98.

    Chysin– Dr. Jothathan Wright mentioned in the seminar on 01/22/00 that chrysin inhibited the aromatization of androstenedione and testosterone to estrogen. Chrysin, a flavone inhibits the action of aromatase, an enzyme that catalyzes the reactions of androstenedione to estrone and testosterone to estradiol. Copyright © 2002 PCCA. All Rights Reserved.

Dermatology

  1. Kincaid, Pharm.D.(C), Michele R. "Options in Wound Care." International Journal of Pharmaceutical Compounding Vol. 6, No. 2, (2002): 92 - 95.
  2. Kuntz, Pharm.D., Rachael. "Sensitization Therapy for Warts." International Journal of Pharmaceutical Compounding Vol. 7, No. 4, (2003): 282 - 270.

Dental

  1. Paoletti, RPh, Jim, Kayda McCord "Compounding Mouthwashes and Rinses for Oral Ulcerations." International Journal of Pharmaceutical Compounding Vol. 3, No. 1, (1999): 8 - 10.
  2. Vail, Jane. "Compounding for Diseases of the Oral Cavity: A Discussion with Stu Sommerville, R,Ph." International Journal of Pharmaceutical Compounding Vol. 6, No. 1, (2002): 16 - 18.

General Practitioner (Family Practice, Internal Medicine, Etc.)

  1. Berrettini, RPh, Lee. "Osteoarthritis: Other Options." International Journal of Pharmaceutical Compounding Vol. 3, No. 6, (1999): 433 - 436.
  2. Carroll, John. "Treating Patients with Asthma." International Journal of Pharmaceutical Compounding Vol. 1, No. 6, (1997): 389 - 391.
  3. Manuel, Julie, and Gina Ford, RPh. "Topical Ketoprofen For Fibromyalgia." International Journal of Pharmaceutical Compounding Vol. 2, No. 6, (1998): 433.
  4. Mecce, RPh, FACA, CDF, Jerry. "The Role of the Pharmacist in Diabetes Care." International Journal of Pharmaceutical Compounding Vol. 7, No. 5, (2003): 341 - 344.
  5. Mecce, RPh, FACA, CDF, Jerry. "Five Compounds for Treating Diabetes - Related Conditions." International Journal of Pharmaceutical Compounding Vol. 7, No. 3, (2003): 170 - 174.
  6. Milner, ND, Martin. "Wilson's Syndrome and T3 Therapy - A Clinical Guide to Safe and Effective Patient Management." International Journal of Pharmaceutical Compounding Vol. 3, No. 5, (1999): 344 - 351.
  7. Osburn, Pharm.D.(C), Jennifer. "Estrogen Replacement Therapy in the Treatment of Alzheimer's Disease." International Journal of Pharmaceutical Compounding Vol. 6, No. 3, (2002): 171 - 176.
  8. Pratt, RPh, BS, Sam. "Minimizing the Risk of Cholesterol - Lowering Therapy." International Journal of Pharmaceutical Compounding Vol. 5, No. 5, (2001): 362 - 364.

Hospice/Pallaitive Care

  1. Carlin, RPh, SCM, NDN, HU, FET, Maureen A. "Hospice and the Role of the Compounding Pharmacist." International Journal of Pharmaceutical Compounding Vol. 4, No. 4, (2000): 247 - 250.
  2. Petrin, RPh, FACA, FIACP, Ronald L. "The Sympton Relief Kit for Hospice Patients." International Journal of Pharmaceutical Compounding Vol. 2, No. 2, (1998): 116 - 117.
  3. Wood, BSPharm, Robert M. "Ketamine for Pain in Hospice Patients." International Journal of Pharmaceutical Compounding Vol. 4, No. 4, (2000): 253 - 254.

Pain Management/Sports Medicine

  1. Airaksinen, O., et al., “Ketoprofen 2.5% gel versus placebo in the treatment of acute soft tissue injuries” International Journal of Clinical Pharmacology - Thertoxicol Vol. 31, (1993): 561 - 563.

    Abstract: “In 1993, Airaksinen et al. published a randomized, double-blind parallel study investigating the efficacy of ketoprofen 2.5% gen versus placebo in 56 patients with acute, minor, soft tissue injuries, (diagnosis not specified.) 24 of 29 patients (82.8%) in the ketoprofen group reported improvement compared with 14 of 27 patients (51.8%) in the control group.”

  2. Ballerini, R., et al, "Absorption rate of ketoprofin topically administered in man: comparison between tissue and plasma levels" Journal of Clinical Pharmacology Research Vol. VI, (1986): 69 - 72.

    Abstract: “The transcutaneous passage of ketoprofen gel topically administered and it distribution in the inner part of the knee joint was evaluated. The fluid samples from patients using topical ketoprofen were about 100 times higher in the sampled tissue levels than in the plasma concentration drawn at the same time”

  3. Chi, S.C., and H.W. Jun "Release rates of ketoprofen from poloxamer gels in a membraneless diffusion cell" Journal of Parmaceut Science Vol. 80, (1991): 200 - 203.
  4. Chlud, K., “Per cutaneous therapy of painful arthritis” Therapeutusche Umschau Vol. 48, No. 1, (1991) : 42 - 45.

    Abstract: “NSAIDs administered as cream, gel or spray, quickly penetrate thought the corneal layer at the application site and reach high effective concentrations in subcutis, fasciae, tendons, ligaments and muscles, but lesser in joint-capsule and fluid indicating direct penetration. Blood levels of topical NSAIDs are extremely low with no systemic side effects. By contrast, oral NSAIDs lead primarily via high blood levels to a much lesser concentration - only one tenth - in particular soft tissues with a high incidence of side effects”

  5. "Compounding for Athletes: Common Questions About Sports Medicine." International Journal of Pharmaceutical Compounding Vol. 3, No. 4, (1999): 285 - 287.
  6. Crowley, Pharm.D., John A. Flores, M.D., M.S., Christine N. Hughes, BA, and Robert P. Iacono, M.D., FACS "Clinical Application of Ketamine Ointment in the Treatment of Sympathetically Maintained Pain." International Journal of Pharmaceutical Compounding Vol. 2, No. 2, (1998): 122 - 127.
  7. Doogan, D.P., “Topical NSAIDs” Lancet Vol. 2. (1989) : 1270 - 1271.

    Abstract: Topically applied NSAID blood concentrations reach only 5-10% of those achieved after oral or IM administration; thus, renal impairment, drug interactions (e.g., warfarin), and adverse GI reactions following topical administration have been considered unlikely”

  8. Flouvant, B. et al, "Pharmacokinetics of ketoprofen in man after repeated per cutaneous administration" Arzneimittel-Forschung Vol. 39, No. 7, (1989): 812 - 815.

    Abstract: “A topical formulation of ketoprofen 2.5%, corresponding to an oral dose of 375mg, was tested on subjects. Plasma samples were collected after the first dose and after 10days of chronic treatment. Urine was also collected. Results of the assay showed that the plasma concentration was 2.6% of the daily applied dose. There was no sign of local intolerance”

  9. Grahame, R. "Transdermal Non-Steroidal Anti-Inflammatory Agents" British Journal of Clinical Practice Vol. 49, No. 1, (1995).

    Abstract: “Over the past 15 years, some six topical NSAIDs have been licensed in the UK, and a nuimber of others are available in other countries or are under investigation. There is a growing body of evidence attesting to the efficacy of topical NSAIDs in the treatment of acute soft-tissue injury and chronic soft-tissue overuse lesions. It has been estimated that 30% of the overall cost of treating arthritis in the USA is spent on treating the GI side effects of oral NSAIDs. Extrapolating this figure to the whole of the country results in the starting sum of US$8.6bn.”

  10. Hosie, G. and H. Bird, "The Topical NSAID felbinac vs. oral NSAIDS: A critical review" European Jounral of Rheumatology and Inflmation Vol. 14, No. 4, (1994): 21 - 28.

    Abstract: “Four separate multi center, double-blind, double-dummy clinical trials have shown that the efficacy of the topical NSAID felbinac is equivalent to that of the oral NSAID ibuprofen in the treatment of soft tissue injuries, and to that of oral ibuprofen in mild to moderate osteo-arthritis. Consequently, because of NSAID side effects, the topical felbinac treatment is a logical treatment alternative from an economic view point as well as for reasons of efficacy and safety”

  11. Marks, R., and P. Dykes, “Plasma and cutaneous drug levels after topical application of piroxicam: a study in healthy volunteers” Skin Pharmocology Vol. 7, No. 6, (1994) : 340 - 344.

    Abstract: “Two studies of healthy males and females (aged 18-65 years) were undertaken to determine plasma and cutaneous levels of piroxicam get following topical application. It may be concluded that piroxicam rapidly permeates thought the stratum corneum into the epidermis/dermis after application of the gel. Low and undetectable plasma levels of drug were observed after topical application”

  12. Mediars, "UID 93058480" Journal of Pharmacology Science Vol. 81, No. 9, : 871 - 874.

    Abstract: “Organogels were studied as matrices for the transdermal transport of drugs in 1992. Preliminary histological studies showed that the gels have no harmful effect when applied to the skin for prolonged periods. The study concluded that lecithin organogel may be an efficient vehicle for the transdermal transport of various drugs.”

  13. Puttini, P.S., and I. Caruso "Primary fibromyalgia syndrome and 5-hydroxy-L-tryophan: One 90-day open study" Journal of International Medical Research Vol. 20. (1992): 182 - 189.
  14. Roderick, K. "Portland Conference highlights international fibromyalgia research advances" CFIDS & Fibromyalgia Healthwatch Vol. 20. (1997): 6 - 7.
  15. Russell, A.L., "Piroxicam 0.5% topical gel compared to placebo in the treatment of acute soft tissue injuries: A bouble-blind study comparing efficacy and safty" Clinical Investigative Medicine Vol. 14, (1991): 35 - 43.

    Abstract: "Advantages of transcutaneous delivery included GI track circumvention and avoidance of first-pass metabolism”

  16. Shad, A.K., G. Wei, R.C. Lanman, et al "Percutaneous absorption of ketoprofen from different anatomical site in man" Pharmaceut Research Vol. 13. (1996): 168 - 172.
  17. Shift, Ebner, et al "Use of topical NSAIDs in patients receiving systemic NSAID treatment: A pharmacy-based study in Germany" Journal of Clinical Epidermatology Vol. 50. (1997): 217 - 218.

    Abstract: "Transdermal application of NSAIDs have been used in Europe for the past 15 years and account fo 2/3rds of the most frequently proscribed NSAIDS in Germany "

  18. Treffel, P. and B. Gabard, “Feasibility of measuring the bioavailability of topical ibuprofen in commercial formulations” Skin Pharmacology Vol.6, No. 4, (1993): 268 - 275.

    Abstract: “Increasing the amount of drug in the epidermis correlated with an increased inhibition of the inflammation. The gel formulation released more drug to the skin and produced a greater anti-inflammatory effect”

  19. Vidrine, PD, FACA, Eric. "Compounding for Pain Management." International Journal of Pharmaceutical Compounding Vol. 2, No. 2, (1998): 104 - 106.

Pediatrics

  1. King, CphT, Erin, and Steve Toney, RPh. "Topical Secretion for the Treatment of Autism." International Journal of Pharmaceutical Compounding Vol. 5, No. 6, (2001): 436 - 437.
  2. Nahata, Pharm.D., Milap C. "Extemporaneous Formulation in Pediatric Patients." International Journal of Pharmaceutical Compounding Vol. 3, No. 4, (1999): 274 - 276.
  3. "Topical Niacinamide for Acne." PCCA (2002).

    Acne vulgaris is a difficult problem to treat. The pathogens are becoming increasingly resistant to the antimicrobials that have been useful and effective treatments in the past. Because of this resistance, new treatments are being sought that are non-antimicrobial in nature. Niacinamide gel provides potent anti-inflammatory activity without the risk of inducing bacterial resistance. Studies have shown that topical 4% Niacinamide gel BID is comparable to 1% Clindamycin gel in efficacy, showing that niacinamide gel is a desirable alternative treatment for acne vulgaris. Copyright © 2002 PCCA, All Rights Reserved

Podiatry

Radiology/Oncology

  1. D'Amico, A.V., Loffredo D.Schultz, R. Dugal, M. Hurwitz, I. Kaplan, C.J. Beard, A.A. Renshaw and P.W. Kantoff "External Bean Radiation 2000." Jama Vol. 284, No. 10, (2000): 1280 - 1283.
  2. Moore, M.D., Erin M., thomas J. Magrino, M.D., and Peter A.S. Johnstone, M.D. "Rectal Bleeding After Radiation Therapy for Prostate Cancer: Endoscopic Evaluation." Radiology Vol. 217, (2000): 215 - 218.

Veterinary

  1. Davidson, BS, RPh, NICVP "Evalvating Transdermal Medication Form of Veterinary Patient, Part 1." International Journal of Pharmaceutical Compounding Vol. 5, No. 2, (2001): 95 - 96.
  2. Davidson, BS, RPh, NICVP "Evalvating Transdermal Medication Form of Veterinary Patient, Part 2." International Journal of Pharmaceutical Compounding Vol. 5, No. 3, (2001): 214 - 215.
  3. Davidson, BS, RPh, NICVP "Evalvating Transdermal Medication Form of Veterinary Patient, Part 3: Methimazole." International Journal of Pharmaceutical Compounding Vol. 5, No. 4, (2001): 282 - 283.

Lifestyle Therapies

Adrenal Fatigue, Cortisol Regulation-- Cortisone Supplementation

  1. Baron-Faust, Rita, Jill P. Buyon, M.D.The Autoimmune Connection: Essential Information for women on Diagnisis, Treatment, and Getting On With Your Life. McGraw-Hill, 2004.
  2. Talbott, Ph.D., Shawn, William Kraemer, Ph.D.. The Cortisol Connection: Why Stress Makes You Fat and Ruins Your Health-- And What You Can Do About It. Hunter House, 2002.
  3. Wilson, N.D., D.C., Ph.D., James L. Adrenal Fatigue. Petaluma: Smart Publications, 2001.

Eicosanoid Regulation– Omega-3 Fish Oil

  1. Sears, Ph.D., Barry. The Omega Rx Zone. New York: Regan Books, 2002.
  2. Stoll, M.D., Andrew L. The Omega-3 Connection. New York: Simon & Schuster, 2001.

Functional Thyroid Deficiency– T3 Supplementation

  1. Arem, M.D., Ridha. The Thyroid Solution. New York: Ballantine Books, August 2000.
  2. Langer, M.D., Stephen E., and James F. Scheer. Solved: The Riddle of Illness. Los Angeles: Keats Publishing, 2000.

Insulin Regulation– Glycemic Index

  1. Agatston, M.D., Arthur. The South Beach Diet. New York: Rodale Press, 2003.
  2. Brand-Miller, Pd.D., Jennie, Thomas M.S. Wolever, M.D., Ph.D., Kaye Foster-Powell, M. Nutr. & Diet,and Stephen Colagiuri, M.D. The New Glucose Revolution. New York: Marlowe & Company, 2003.
  3. Schwarzbein, Dianna, M.D., Nancy Deville. The Schwarzbein Principle: The Truth About Losing Weight, Being Healthy, and Feeling Younger. Health Communicatons, 1999.
  4. Schwarzbein, Dianna, M.D., Marilyn Brown. The Schwarzbein Principle II: The "Transition" -- A Regeneration Program to Prevent and Reverse Accelerated Aging. Health Communicatons, 2002.
  5. Schwarzbein, Dianna, M.D., et. al.The Schwarzbein Principle Cookbook. Health Communicatons, 1999.
  6. Schwarzbein, Dianna, M.D., et. al.The Schwarzbein Principle Vegetarian Cookbook. Health Communicatons, 1999.
  7. Woodruff, M.S., R.D., Sandra. The Good Carb Cookbook. New York: Avery, 2001.

Natural Hormone Replacement (Women)– TriEst or BiEst Supplementation with DHEA and Testosterone

  1. Gillson, M.D., Ph.D., George, and Tracy Marsden, BscPharm. You’ve Hit Menopause: Now What? 3 Simple Steps to Restoring Hormone Balance. Calgary: Blitzprint, 2003.
  2. Laux, N.D., Marcus, and Christine Conrad. Natural Woman, Natural Menopause. New York: Harper-Collins Publishers, 1997.
  3. Platt, M.D., Michael E. Natural Hormone Therapy - For Men Women & Children. Rancho Mirage: We Publish Books, 2004.
  4. Reiss, M.D., Uzzi, and Martin Zucker. Natural Hormone Balance for Women. New York: Pocket Books, 2001.
  5. Schwartz, M.D., Erike. The 30-Day Natural Hormone Plan: Look and Feel Young Again without Synthetic HRT. Warner Books, 2004.
  6. Sommers,Suzanne. The Sexy Years: Discover the Hormone Connection-- The Secret to Fabulous Sex, Great Health, and Vitality for Women and Men. Crown Publishing Group, 2004.
  7. Wright, M.D., Jonathan V., and John Morgenthaler. Natural Hormone Replacement. Petaluma: Smart Publications, 1997.

Pain Control with Motion Exercise

  1. Egoscue, Peter, and Roger Gittines. Pain Free - A Revolutionary Method for Stopping Chronic Pain. New York: Bantam Press, 2000.
  2. Egoscue, Peter, and Roger Gittines. The Egoscue Method of Health Through Motion. New York: Quill, 2001.

Testosterone Syndrome (Men)– Testosterone Supplementation with DHEA & Crysin

  1. Shippen, M.D., Eugene, and William Fryer. The Testosterone Syndrome. City: M. Evans and Company, 1989.
  2. Tan, M.D., Robert S. The Andropause Mystery- Unraveling truths about the Male Menopause. Houston: AMRED Publishing, 2001.
  3. Wright, M.D., Jonathan V., and Lane Lenard, Ph.D. Maximize Your Vitality & Potency- For Men Over 40. Petaluma: Smart Publications, 2000.

Trigger Points and Pain Control

ICP - Providing quality solutions with maximum benefits for a healthier you.
Reference Search
© Copyright 2003 - 2010 Inland Compounding Pharmacy. All rights reserved.